Welcome to our dedicated page for ELOS news (Ticker: ELOS), a resource for investors and traders seeking the latest updates and insights on ELOS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ELOS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ELOS's position in the market.
Epitomee Medical (TASE: EPIT) has received FDA clearance for its Epitomee® Capsule, a novel ingestible weight management device for adults with a BMI of 25-40 kg/m². This drug-free prescription solution works mechanically by creating a 3D matrix in the stomach, promoting a feeling of fullness. The FDA clearance follows the successful RESET study, a randomized, double-blind, placebo-controlled trial involving 279 participants across 9 U.S. sites. Key findings include:
- Significantly better weight loss in the device group (P<0.0001)
- 55.5% of subjects achieved ≥5% weight loss at 24 weeks
- Favorable safety profile with no serious adverse device effects
- Improved quality of life for treated subjects
The company is now seeking strategic partnerships to bring this innovative product to the U.S. market.
